Why Cannabis Stocks Jumped By Double Digits And Why Analysts Say 'Don't Drink The Kool-Aid In One Gulp' Cannabis stocks jumped as Trump reportedly pushes SAFE Banking behind the scenes—but analysts warn: don't chase the hype just yet.
What's Going On With Tilray Brands Stock Today? Tilray launches new whiskey. Recently it planned a reverse split to meet Nasdaq listing standards.
Philip Morris (PM) To Report Earnings Tomorrow: Here Is What To Expect Tobacco company Philip Morris International (
NYSE:PM )
will be reporting earnings tomorrow before market open. Here’s what investors should know.
The Canadian Cannabis Report- Mondaty April 21 The past, present, and future of the Canadian cannabis sector.
Tilray Stock Hit A New 52-Week Low Today: What's Going On? Tilray shares are trading lower by 6.2% during Thursday's session. The company on Thursday announced plans to implement a reverse stock split.
Why Cannabis Co. Tilray (TLRY) Is Trading Down Today Tilray shares fall 6.8% after announcing a proposed reverse stock split ahead of a June 10 shareholder vote.
Vegan, Sugar-Free, And Now In Australia: Tilray's Edibles Aren't Your Average Medical Launch Tilray Brands Inc. (
NASDAQ: TLRY ) has launched its first medical cannabis edibles in Australia through Tilray Medical. The new sugar-free, vegan Good Supply Pastilles offer THC and CBD options, enhancing patient access to plant-based therapies.
The Canasian Cannabis Report- Monday, April 14 The past, present and futur eof the Canasian cannabis sector.
The Week In Cannabis: Delays, Decrees And Deals Reshape The Global Playbook Cannabis news of the week: Germany holds CanG, US delays, Chile bill; Italy hemp ban; SNDL expands, Tilray cuts outlook, US sales forecast –$21 B.
The Canadian Cannabis Report- Monday, April 7 The past, present, and future of the Canadian cannabis sector.
Why Tilray (TLRY) Stock Is Trading Lower Today Shares of cannabis company Tilray Brands (
NASDAQ:TLRY )
fell 19.7% in the afternoon session after the company reported weak fiscal third-quarter 2025 results that missed analysts' sales and EBITDA estimates, signaling ongoing challenges in growing its top line.
